HDAC6-IN-34, identified by its CAS number 1432508-73-0, is a small molecule inhibitor specifically targeting histone deacetylase 6 (HDAC6), an enzyme involved in various cellular processes, including the regulation of gene expression and protein degradation. This compound is part of a broader class of HDAC inhibitors that have garnered interest for their potential therapeutic applications in cancer and neurodegenerative diseases. HDAC6 is unique among the HDAC family due to its role in deacetylating non-histone proteins, influencing cellular stress responses and protein homeostasis. The inhibition of HDAC6 can lead to increased acetylation of target proteins, which may enhance their stability and function. HDAC6-IN-34 is characterized by its specific binding affinity to the enzyme, which can result in altered cellular signaling pathways. Research into this compound is ongoing, focusing on its efficacy, safety profile, and potential as a therapeutic agent in various disease contexts. As with many experimental compounds, detailed pharmacokinetic and pharmacodynamic properties are critical for understanding its biological effects.

HDAC6-IN-34

1432508-73-0: HDAC6-IN-34, identified by its CAS number 1432508-73-0, is a small molecule inhibitor specifically targeting histone deacetylase 6 (HDAC6), an enzyme involved in various cellular processes, including the regulation of gene expression and protein degradation. This compound is part of a broader class of HDAC inhibitors that have garnered interest for their potential therapeutic applications in cancer and neurodegenerative diseases. HDAC6 is unique among the HDAC family due to its role in deacetylating non-histone proteins, influencing cellular stress responses and protein homeostasis. The inhibition of HDAC6 can lead to increased acetylation of target proteins, which may enhance their stability and function. HDAC6-IN-34 is characterized by its specific binding affinity to the enzyme, which can result in altered cellular signaling pathways. Research into this compound is ongoing, focusing on its efficacy, safety profile, and potential as a therapeutic agent in various disease contexts. As with many experimental compounds, detailed pharmacokinetic and pharmacodynamic properties are critical for understanding its biological effects.

<p>HDAC6-IN-34 (compound 21), an orally active, selective HDAC6 inhibitor, exhibits an IC50 of 18 nM. It enhances tubulin acetylation levels without impacting histone acetylation in cutaneous T-cell lymphoma cells and suppresses TNF-α secretion in LPS-stimulated macrophage cells. Furthermore, HDAC6-IN-34 demonstrates outstanding anti-arthritic efficacy in rats [1].</p>

CAS 1432508-73-0

HDAC6-IN-34

HDAC6-IN-34

Ref: TM-T86555